SMCHD1抗体;SMCHD1 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using ITGB5 mouse mAb (green) and negative control (red).    

  
  

SMCHD1 (Structural Maintenance of Chromosomes Hinge Domain-containing protein 1) is an epigenetic regulator critical for maintaining chromatin architecture and gene silencing, particularly in X-chromosome inactivation and genomic imprinting. Discovered in 2008. SMCHD1 belongs to the SMC protein family but differs from canonical SMC complexes by functioning as a monomer. It contains a conserved hinge domain essential for its chromatin-clamping activity, enabling long-range chromatin interactions and repression of gene clusters.

SMCHD1 antibodies are vital tools for studying its role in developmental disorders and diseases. Mutations in SMCHD1 are linked to facioscapulohumeral muscular dystrophy (FSHD) type 2 and Bosma arhinia microphthalmia syndrome (BAMS). In FSHD2. SMCHD1 dysfunction synergizes with DUX4 expression to cause muscle degeneration, while BAMS mutations disrupt craniofacial development. Researchers use SMCHD1 antibodies in techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP) to investigate its localization, protein interactions, and chromatin remodeling mechanisms.

Recent studies also explore SMCHD1 as a therapeutic target, leveraging antibodies to modulate its activity in epigenetic editing or small-molecule screens. Its dual role in gene silencing and disease pathogenesis continues to drive antibody development for both diagnostic and functional studies.